Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Underlying ideological foundations of stigma and equipment inadequacy include thin-centrism and inadequate representation of fat people in health care organizational leadership.
AMA J Ethics. 2023;25(7):E528-534. doi:
10.1001/amajethics.2023.528.
The picture that emerges from study of physician economic behavior is mixed, but from the intensity of responses by some professional societies to Medicare's coding modifier proposal, it appears that economic incentives matter a lot to many of their members.
Some behavioral economists caution that, as ACOs proliferate, their focus on financial incentives could compromise hospitals’ mission and organizational behaviors.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.